ZA202002292B - Methods of treating heart failure with preserved ejection fraction - Google Patents

Methods of treating heart failure with preserved ejection fraction

Info

Publication number
ZA202002292B
ZA202002292B ZA2020/02292A ZA202002292A ZA202002292B ZA 202002292 B ZA202002292 B ZA 202002292B ZA 2020/02292 A ZA2020/02292 A ZA 2020/02292A ZA 202002292 A ZA202002292 A ZA 202002292A ZA 202002292 B ZA202002292 B ZA 202002292B
Authority
ZA
South Africa
Prior art keywords
methods
heart failure
ejection fraction
treating heart
preserved ejection
Prior art date
Application number
ZA2020/02292A
Other languages
English (en)
Inventor
Hallakou-Bozec Sophie
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of ZA202002292B publication Critical patent/ZA202002292B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2020/02292A 2017-10-02 2020-05-04 Methods of treating heart failure with preserved ejection fraction ZA202002292B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566668P 2017-10-02 2017-10-02
PCT/IB2018/057648 WO2019069230A1 (en) 2017-10-02 2018-10-02 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION

Publications (1)

Publication Number Publication Date
ZA202002292B true ZA202002292B (en) 2022-12-21

Family

ID=63963334

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/02292A ZA202002292B (en) 2017-10-02 2020-05-04 Methods of treating heart failure with preserved ejection fraction

Country Status (12)

Country Link
US (1) US11617754B2 (https=)
EP (1) EP3691650A1 (https=)
JP (1) JP2020536121A (https=)
KR (1) KR20200102982A (https=)
CN (1) CN111163782A (https=)
BR (1) BR112020006472A2 (https=)
CA (1) CA3078163A1 (https=)
IL (1) IL273723A (https=)
MX (1) MX2020003243A (https=)
TW (1) TW201924689A (https=)
WO (1) WO2019069230A1 (https=)
ZA (1) ZA202002292B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
CN115770062B (zh) * 2021-09-07 2025-10-10 深圳迈瑞生物医疗电子股份有限公司 一种超声波数据的处理方法、成像装置
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
KR101618198B1 (ko) 2008-05-23 2016-05-04 뽁셀 에스아에스 3,6-디히드로-1,3,5-트리아진 유도체의 제조방법
BRPI0916197B1 (pt) 2008-07-29 2018-01-23 Poxel Processo para isolar componentes enantioméricos de uma mistura de enantiômeros
TW201033182A (en) 2008-12-12 2010-09-16 Poxel Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
US8592370B2 (en) 2008-12-12 2013-11-26 Poxel S.A.S. Combination of insulin with triazine derivatives
JP5536869B2 (ja) 2009-03-26 2014-07-02 ポクセル・エスアーエス 優先晶出法を利用したジヒドロ−1,3,5トリアジンラセミ体のエナンチオマー分離のための方法
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
WO2011154496A1 (en) * 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第2型糖尿病之治療
US8742103B2 (en) 2010-12-01 2014-06-03 Poxel Separation of triazine derivatives enantiomers using tartaric acid
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US10285973B2 (en) 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
BR112018016001A2 (en) * 2016-03-16 2018-12-18 Boehringer Ingelheim International Gmbh pharmaceutical composition, treatment methods and uses thereof
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease

Also Published As

Publication number Publication date
WO2019069230A1 (en) 2019-04-11
CA3078163A1 (en) 2019-04-11
IL273723A (en) 2020-05-31
CN111163782A (zh) 2020-05-15
TW201924689A (zh) 2019-07-01
US11617754B2 (en) 2023-04-04
US20200316078A1 (en) 2020-10-08
MX2020003243A (es) 2020-09-18
JP2020536121A (ja) 2020-12-10
KR20200102982A (ko) 2020-09-01
EP3691650A1 (en) 2020-08-12
BR112020006472A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
PL3500330T3 (pl) Zespoły cewnika z zaworem i powiązane sposoby
EP3171786A4 (en) Devices and methods for treating heart failure
ZA201705673B (en) Methods for treating skin
IL253954B (en) Implantable devices and related methods for heart failure monitoring
IL274865A (en) Treatment methods with asparaginase
ZA202002292B (en) Methods of treating heart failure with preserved ejection fraction
HUE069805T2 (hu) Szívelégtelenség szívizomszarkomer-aktivátorokkal történõ kezelésére szolgáló eljárások
ZA201706257B (en) Treatment of wood
SG10201503314VA (en) Valved catheter assemblies and related methods
EP3207940A4 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
IL251852A0 (en) Systems and methods for treating the heart valve
ZA201706059B (en) Method of treatment with tradipitant
PL3352745T3 (pl) Połączenie dofetylidu i meksyletyny w zapobieganiu i leczeniu migotania przedsionków
SG10202008024VA (en) Method for Treating Heart Failure
IS050183A (en) Method of tissue preservation
IL258197A (en) Methods for treating cardiac injury
IL270819A (en) Methods for treating chronic paucity
EP3256137A4 (en) Method of treating heart failure
GB201514303D0 (en) Bifidobacteria for treating cardiac conditions
PL3544624T3 (pl) Leczenie niedywolności serca i niedokrwiennego uszkodzenia reperfuzyjnego serca
EP3089725A4 (en) Method and system for heart pacing
GB201514302D0 (en) Lactobacilli for treating cardiac dysfunction
GB201510481D0 (en) Artificial heart
IL274552A (en) Treatment of side effects of botulinum treatments
HK40019141A (en) Compositions and methods for treating heart failure